Gilead at the 11th International AIDS Society (IAS) Conference on HIV Science
We’re coming to you live from IAS 2021, the world’s largest open scientific conference on HIV/AIDS.
Here is your one-stop shop for everything you need to know—or might have missed—from Gilead at IAS. With over 31 abstracts, including keynote presentations and symposiums—we’ve got a lot to cover.
The data we are presenting at the conference span our diverse medicines and discovery pipeline, reflecting Gilead’s ongoing commitment to scientific innovation, a key pillar to addressing unmet and evolving needs in HIV.
Join us here for on-the-ground coverage from the virtual meeting—we will share updates as they happen, so be sure to check back often.
Gilead announces latest scientific advancements in HIV that will be presented at IAS 2021
Gilead announces new long-term data for triple-therapy, single tablet HIV regimen at IAS 2021
Investigational Long-Acting Therapy
Gilead announces new data findings on investigational long-acting therapy for HIV at IAS 2021
Events of Note
‘Thinking Beyond Lifelong Treatment in HIV’, 18 July, 19:00 – 20:30 CET
A unique opening day session convening community members, researchers, people living with HIV, and partners to examine the process of developing a functional cure for HIV. During the symposium, they will discuss how pursuing a multi-pronged approach to long-term viral remission in the absence of ongoing antiretroviral treatment will be a critical component of making progress toward this goal, and the critical role community collaboration will play. We’re honored to be joined by clinical trial participants, who will share critical insights about what it’s like to be part of a trial and what they’d like researchers to understand about their experiences. Our very own Devi SenGupta, head of Gilead’s HIV Cure Development Program, is joined by:
- Dr. Marina Caskey, The Rockefeller University
- Matthew Chappell, Stanford Health Care
- Cecilia Chung, Transgender Law Center
- Dr. Steve Deeks, University of California, San Francisco
- Dr. Karine Dubé, University of North Carolina, Chapel Hill
- Nombuso Msomi, FRESH: Females Rising through Education, Support and Health
- Dr. Thumbi Ndung’u, Africa Health Research Institute
- Moses “Supercharger” Nsubuga, Joint Adherent Brothers and Sisters Against AIDS
- Dr. Robert F. Siliciano, Howard Hughes Medical Institute, Johns Hopkins University
- Dr. Ole Søgaard, Aarhus University Hospital
Registered IAS attendees are invited to watch the symposium on the IAS platform.
‘Community Talks’, July 29, 2021
Community representatives from around the world come together post-IAS to delve into key takeaways and hot topics stemming from the conference. They’ll also be discussing how these data findings will impact the HIV community at large. This forum allows for unique members of the community to collaborate and have an open discussion.
Our Data and Abstracts
At this year’s IAS conference, we proudly present data from 31 abstracts. Take a look at the table below, which highlights some of the key data being presented at the conference.
The IAS 2021 embargo policy is available here
HIV Treatment Research
Week 72 Outcomes and Covid-19 Impact From the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults Living With HIV
Long-Term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) With Pre-existing Resistance and Viral Blips
Long-Term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-Up
Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged 65 Years or Older: Week 96 Results From an International, Phase 3b, Open-Label Trial
Investigational Long-Acting HIV Research (Lenacapavir)
Long-Acting Subcutaneous Lenacapavir Dosed Every 6 Months as Part of a Combination Regimen in Treatment-Naïve People with HIV: Interim 16-Week Results of a Randomized, Open-Label, Phase 2 Induction-Maintenance Study (CALIBRATE)
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People with HIV: Week 26 Results (CAPELLA study)
HIV Cure Research
Proteomic Evidence of Vesatolimod-induced Enhancement of “Cross-talk” Between Innate and Adaptive Immune Cells in HIV Controllers on ART
HIV Prevention Research
Outcomes of Participants Switching From F/TDF to F/TAF for PrEP: Week 48 Results From the DISCOVER Open Label Phase
Comparing Adherence to HIV Pre-Exposure Prophylaxis (PrEP) Among New, Male PrEP Users Initiating F/TAF vs. F/ TDF
Real-world Utilization of F/TDF and F/TAF for HIV Pre-Exposure Prophylaxis during the COVID-19 Pandemic in the U.S., December 2019 – June 2020
HIV Recent Infection Test-Based Incidence as a Counter Factual for New PrEP Trials
Hear from Gilead leadership, HIV researchers and community representatives about their ‘on-the-virtual-ground’ experiences of IAS 2021 with daily video updates! Tune in to hear more:
Welcome to IAS!
Outcomes of the Gilead ‘Thinking Beyond Lifelong Treatment in HIV’ Symposium
Insights from Researchers on PrEP Innovation
Insights From Researchers on Treatment Innovation
Overview of Key Moments From IAS 2021
Gilead clinical researchers and community partners provide insights and examples of best practices in clinical development for HIV treatment and prevention medicines. Check out our articles on these important partnerships here: